GPI developed price and product allocation strategy

26 April 2021

Using GPI’s data and analytics platform and proprietary methodology we have helped a number of our customers analyse and define their market access strategy. In this case study, we examine how GPI has supported one of the largest players in the plasma-derived space in developing price and product allocation strategy for 2021 across key commercial markets.

The Situation

Immunoglobulin (IG) and Albumin (ALB) markets are highly competitive with branded/local products being procured in masses (tenders) through public or private routes. This results in challenges in commercial & price strategy setting.

Demand for IG and ALB is anticipated to grow over the next 5 years. However, the COVID-19 pandemic has resulted in closure of plasma collection centres across the globe, which has resulted in supply vs. demand dynamic changes and potential expectation of price increases.

The Challenge

The study aimed to provide our client with visibility across key concepts:

• Commercial prices conducted by competition as well as procurement strategies employed
• Gauge opportunity to increase price as well as volumes sold
• Key criteria and market dynamics to monitor for strategy development

The Methodology

Geographical Scope

• IG markets: Germany, Mexico
• ALB markets: Turkey, China, Algeria, Kuwait
• All applicable public and private procurement routes

The Approach

To derive strategic recommendations, GPI brought together, primary input, price-volume data, country policies and insights from market landscape assessment.

The Solution
GPI delivered a ‘’mini book of insights’’ that consisted of:

Impact
GPI provided a framework to clearly measure price and volume opportunity in every market to inform their price/commercial strategy as well as product allocation across a range of key markets during these challenging times.